Q-omics provides the consensus-scored MS4A15 profile across patient tissues and cancer cell-line models. MS4A15 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MS4A15 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, MS4A15 RNA expression shows 10,306 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, and THYM as cancer lineages where MS4A15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A15 survival associations across molecular data types. MS4A15 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A15 RNA expression–survival associations across cancer types. High MS4A15 expression shows unfavorable associations in UCEC, LUSC and BLCA, but favorable associations in LUAD, UCS and BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MS4A15 RNA expression.
This table summarizes MS4A15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MS4A15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A15 shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, COAD, THCA and BRCA. The LUAD box plot shows higher MS4A15 RNA expression in normal versus tumor tissue (log2 FC = −5.598, t-test p < 0.001).
This table shows molecular features associated with MS4A15 in patient tissues and cancer cell lines. In patient samples, MS4A15 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
